comprehensive -WSS

comprehensive

author：hotspot 2025-09-30 00:37:42 - browse：5912

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Kenai launches with $82 million for Parkinson’s stem cell therapy

leisure time

WSS

Why getting cancer drugs just got harder for rural patients

Copay coupons to count toward deductibles, after Biden court move

Prior authorization will have to move faster under new Biden rule

How to fix the rural physician shortage in the U.S.

FogPharma raises $145 million in rare Series E round

Flu vaccine offering decent levels of protection this winter, new data show

hotspot

comprehensive

hotspot

Jerome Adams on the need for new antivirals for Covid

Prior authorization will have to move faster under new Biden rule

Medicare details structure of new drug price negotiation program

Medicare Advantage today, explained in one chart

In Memoriam: Notable people who died in 2023

Medicare Advantage today, explained in one chart

At least 13 dead in Texas as scorching temps continue

How digital therapeutics firms are pivoting after Pear's bankruptcy

Jerome Adams on the need for new antivirals for Covid

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

leisure time

Why getting cancer drugs just got harder for rural patients

ALS groups 'won't be played again' by the FDA, drug sponsors

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Clinical trials giant ICON acquires HumanFirst

How to address the problem of discarded donor organs

Biotech venture capitalists face new demands from investors

Wikipedia

hotspot

leisure time

entertainment